Molecular heterogeneity of triple-negative breast cancer

被引：58
作者：
Abramson V.G. [1 ]
Mayer I.A. [1 ]
机构：
[1] Division of Hematology/Oncology/Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232-6307, 2220 Pierce Avenue
来源：
Current Breast Cancer Reports | 2014年 / 6卷 / 3期
关键词：
Gene expression profiles; Targeted therapy; TNBC; Triple-negative breast cancer;
D O I：
10.1007/s12609-014-0152-1
中图分类号：
学科分类号：
摘要：
Triple-negative breast cancers (TNBCs) are a group of aggressive breast cancers with a greater incidence of relapse, stage-for-stage, than ER/PR-positive and HER2-positive breast cancers, despite optimum loco-regional and systemic therapy. To date, no single targeted therapy has been approved for treatment of TNBC, and cytotoxic chemotherapy remains the standard systemic treatment. Recently, gene expression analysis identified six distinct TNBC subtypes, each with unique biology. In this review we discuss current and forthcoming therapeutic strategies and novel approaches to targeted treatment of these TNBC subtypes. © 2014 Springer Science+Business Media.
引用
收藏
页码：154 / 158
页数：4
相关论文
共 36 条
  • [21] Turner N., Tutt A., Ashworth A., Hallmarks of 'BRCAness' in sporadic cancers, Nat Rev Cancer, 4, 10, pp. 814-819, (2004)
  • [22] Silver D.P., Richardson A.L., Eklund A.C., Wang Z.C., Szallasi Z., Li Q., Et al., Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer, J Clin Oncol, 28, 7, pp. 1145-1153, (2010)
  • [23] Byrski T., Gronwald J., Huzarski T., Grzybowska E., Budryk M., Stawicka M., Et al., Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers, Breast Cancer Res Treat, 108, 2, pp. 289-296, (2008)
  • [24] Von Minckwitz G., Schneeweiss A., Salat C., A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto), J Clin Oncol, 31, SUPPL., (2013)
  • [25] Sikov W., Berry D., Perou C., Singh B., Cirrincione C., Tolaney S., Et al., Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance), San Antonio Breast Cancer Symposium 2013, 5, (2013)
  • [26] Cortazar P., Zhang L., Untch M., Mehta K., Costantino J.P., Wolmark N., Et al., Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis, Lancet, (2014)
  • [27] Turner N., Tutt A., Ashworth A., Targeting the DNA repair defect of BRCA tumours, Curr Opin Pharmacol, 5, 4, pp. 388-393, (2005)
  • [28] Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., Et al., Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy, Nature, 434, 7035, pp. 917-921, (2005)
  • [29] O'Shaughnessy J., Osborne C., Pippen J.E., Yoffe M., Patt D., Rocha C., Et al., Iniparib plus chemotherapy in metastatic triple-negative breast cancer, N Engl J Med, 364, 3, pp. 205-214, (2011)
  • [30] O'Shaughnessy J.S.L., Danso M.A., Et al., A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC), J Clin Oncol, 29, (2011)
1234